EyePoint Pharmaceuticals will distribute Dexycu to one of the largest integrated delivery systems in the U.S. through a new two-year contract, the company announced Dec. 4.
Three things to know:
1. Dexycu is an FDA-approved single intraocular dose for the treatment of postoperative inflammation.
2. EyePoint's new agreement will make Dexycu available to the system's 8.5 million patients, opening new distribution channels in California, Washington, Georgia, Colorado and mid-Atlantic states.
3. The system also granted EyePoint preferred vendor status.
"We continue to receive strong reception and increasing adoption of this innovative product from physicians and [ASCs] across the U.S.," EyePoint President and CEO Nancy Lurker said in a press release. "Dexycu has the potential to replace the burdensome post-cataract surgery steroid regimen by providing an easy-to-administer, extended release treatment option with a favorable safety profile."